- Home
- LSAK vs OBIO Comparison
LSAK vs OBIO Comparison
Compare LSAK & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSAK
- OBIO
- Stock Information
- Founded
- LSAK 1997
- OBIO 2017
- Country
- LSAK South Africa
- OBIO United States
- Employees
- LSAK N/A
- OBIO N/A
- Industry
- LSAK Investment Bankers/Brokers/Service
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- LSAK Finance
- OBIO Health Care
- Exchange
- LSAK Nasdaq
- OBIO Nasdaq
- Market Cap
- LSAK 344.5M
- OBIO 118.8M
- IPO Year
- LSAK N/A
- OBIO N/A
- Fundamental
- Price
- LSAK $4.67
- OBIO $2.96
- Analyst Decision
- LSAK
- OBIO Strong Buy
- Analyst Count
- LSAK 0
- OBIO 5
- Target Price
- LSAK N/A
- OBIO $14.20
- AVG Volume (30 Days)
- LSAK 31.0K
- OBIO 369.8K
- Earning Date
- LSAK 09-03-2025
- OBIO 08-11-2025
- Dividend Yield
- LSAK N/A
- OBIO N/A
- EPS Growth
- LSAK N/A
- OBIO N/A
- EPS
- LSAK N/A
- OBIO N/A
- Revenue
- LSAK $574,080,000.00
- OBIO $2,886,000.00
- Revenue This Year
- LSAK $1.06
- OBIO $20.47
- Revenue Next Year
- LSAK $13.32
- OBIO $11.45
- P/E Ratio
- LSAK N/A
- OBIO N/A
- Revenue Growth
- LSAK 4.13
- OBIO 30.23
- 52 Week Low
- LSAK $3.39
- OBIO $2.37
- 52 Week High
- LSAK $5.60
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- LSAK 63.29
- OBIO 51.30
- Support Level
- LSAK $4.45
- OBIO $2.78
- Resistance Level
- LSAK $4.75
- OBIO $2.94
- Average True Range (ATR)
- LSAK 0.22
- OBIO 0.21
- MACD
- LSAK 0.04
- OBIO -0.00
- Stochastic Oscillator
- LSAK 91.11
- OBIO 60.87
About LSAK Lesaka Technologies Inc.
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates two reportable segments: Merchant and Consumer. The company operates mainly within South Africa. The Merchant segment that derives majority revenue includes activities related to the provision of goods and services provided to corporate and other juristic entities. It earns fees from processing activities performed for its customers and revenue generated from the distribution of prepaid airtime. The Consumer segment includes activities related to the provision of financial services to customers, including bank accounts, loans, and insurance products. The firm charges monthly administration fees for all bank accounts.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.